Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
2000
Variant EGF Receptor in Prostate Cancer
publication
Author Information
Author(s): Olapade-Olaopa E O, Moscatello D K, MacKay E H, Horsburgh T, Sandhu D P S, Terry T R, Wong A J, Habib F K
Hypothesis
The presence of a variant EGF receptor protein (EGFRvIII) is responsible for the depletion of EGFR protein expression in prostatic cancer.
Conclusion
The study found that the variant EGFRvIII is highly expressed in malignant prostatic tissues, suggesting its role in cancer progression.
Supporting Evidence
- Earlier studies showed a depletion of EGFR protein expression in prostatic cancer.
- The variant EGFRvIII was not found in normal prostatic glands.
- EGFRvIII levels increased with the transformation of tissues to a malignant phenotype.
Takeaway
This study shows that a special type of EGF receptor is found more in prostate cancer, which could help in treating the disease.
Methodology
A retrospective study examining normal, benign, and malignant prostatic tissues for the presence of EGFRvIII at the mRNA and protein levels.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website